Table 1 Patient baseline characteristics

From: The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease

Variable

Olmesartan, n=22

Non-ARB, n=23

P-value

Age (years); mean (s.d.)

64.7±10.4

67.0±7.9

0.413

Male (%)

86

87

1.000

Waist circumference (cm); mean (s.d.)

88.3±7.7

90.1±10.1

0.892

Diabetes (%)

41

51

0.554

CKD stage (n)

  

0.167

 Stage 1

0

0

 

 Stage 2

6

1

 

 Stage 3

10

16

 

 Stage 4

3

4

 

 Stage 5

3

2

 

Serum creatinine (mg dl−1); mean (s.d.)

1.73±1.04

1.73±1.10

0.742

eGFR (ml min−1 per 1.73 m2); mean (s.d.)

43.0±22.2

40.5±17.9

0.751

UPCR (g per g Cr); mean (s.d.)

2.12±2.58

1.58±2.23

0.517

UACR (mg per g Cr); mean (s.d.)

1605.3±1889.7

1182.0±1614.9

0.388

hs-CRP (mg dl−1); mean (s.d.)

0.14±0.17

0.07±0.05

0.175

Urinary AGT (μg per g Cr); mean (s.d.)

514.8±843.3

454.3±811.3

0.835

Urinary 8-OHdG (ng per mg Cr); mean (s.d.)

3.60±3.53

2.65±2.74

0.455

Urinary type IV collagen (μg per g Cr); mean (s.d.)

12.70±12.72

8.78±8.85

0.301

  1. Abbreviations: ARB, angiotensin II type 1 receptor blocker; AGT, angiotensinogen; CDK, chronic kidney disease; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity c-reactive protein; 8-OHdG, 8-hydroxydeoxyguanosine; UACR, urinary albumin-to-creatinine ratio; UPCR, urinary protein-to-creatinine ratio.
Back to article page